01Dec
Americas Antitrust Review 2021
Covid-19 has made 2020 into a year like no other with ‘stay at home’ orders and working from home the new normal. Nonetheless, the tech and pharma industries continued to attract immense antitrust scrutiny, with daily reports in the media and pressure from politicians to address what some perceive to be anticompetitive mergers by digital platforms and pharmaceutical companies, even while innovation in both sectors continues at breakneck speed. In this article, we discuss some of the most...
By:
Cooley LLP
Related
For international investors looking at opportunities in China, this summer has been largely a waitin...
Read More >
Under the new Massachusetts Paid Family Leave Law, M.G.L c. 175M (“MAPFML”), employees and other c...
Read More >
In Walmart Stores, Inc., 368 NLRB No. 24 (July 25, 2019), a majority of the National Labor Relations...
Read More >
On July 31, 2019, OFCCP Director Craig Leen gave the opening remarks at the National Industry Liaiso...
Read More >
The Internal Revenue Service issued a Private Letter Ruling (PLR) stating that certain genetic testi...
Read More >
Seeking to piggyback on the State of Emergency Governor Gavin Newsom declared on March 4, 2020 as pa...
Read More >